PTC Therapeutics
PTCT
204 hedge funds and large institutions have $3.3B invested in PTC Therapeutics in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 84 increasing their positions, 65 reducing their positions, and 28 closing their positions.
288% more call options, than puts
Call options by funds: $18.4M | Put options by funds: $4.76M
29% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 65
11% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 28
2.96% more ownership
Funds ownership: 106.33% → 109.3% (+3%)
1% more funds holding
Funds holding: 202 → 204 (+2)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
13% less capital invested
Capital invested by funds: $3.81B → $3.3B (-$502M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$39.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$32.8M |
| 3 |
BlackRock
New York
|
+$29.2M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$19.6M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$57.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$20.4M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$12.6M |
| 4 |
Holocene Advisors
New York
|
-$11.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.3M |
PTCT Hedge Fund Activity: Q2 2023 in Review
204 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2023, worth a combined $3.3B — down 13% from $3.81B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new PTCT positions and 28 closed out — a net gain of 3 holders — while 84 added to existing stakes and 65 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $39.1M. The largest seller was Adage Capital Partners, cutting an estimated $57.2M.
- 204 institutional investors held PTC Therapeutics (PTCT) as of Q2 2023, up from 202 in Q1 2023.
- Funds reported $3.3B of PTC Therapeutics stock for Q2 2023, down 13% quarter-over-quarter.
- 31 funds opened new PTC Therapeutics positions in Q2 2023 and 28 closed out, a net change of +3 holders.
- The largest PTC Therapeutics buyer in Q2 2023 was Cowen and Company, an estimated $39.1M added.
- The largest PTC Therapeutics seller in Q2 2023 was Adage Capital Partners, an estimated $57.2M sold.
Based on aggregated 13F filings for Q2 2023.